Struggling genetic testing 23andMe is looking for a buyer for the virtual care business it acquired in 2021, Business Insider ...
23andMe has been exploring a possible sale of its telehealth business, Business Insider has learned. The struggling health company bought virtual care startup Lemonaid in 2021 for $400 million.
The struggling health company bought virtual care startup Lemonaid in 2021 for $400 million. 23andMe's stock has plummeted after a 2023 data breach exposed millions of customer accounts.
Me (ME) has been quietly exploring a possible sale of its telehealth business, Lemonaid, according to Business Insider.Stay Ahead of the ...
Genetic testing firm 23andMe is reportedly considering the sale of its telehealth division, Lemonaid Health, according to ...
The Lung Cancer Genetics Study, a collaboration between lung cancer advocacy organizations, aims to explore the genetics of lung cancer ...
23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses. The company that made its name by providing saliva ...
Lipoprotein(a) is well established as a risk factor for cardiovascular disease, but patients rarely get tested for it. Now, an alliance between Novartis and genetic testing specialist 23andMe is ...
Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...
After hours: January 17 at 7:58:38 p.m. EST ...
Pre-market: 9:08:12 am GMT-5 ...